Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EBV TCR T cell therapy

Drug Profile

EBV TCR T cell therapy

Alternative Names: EBV-TCR-T (YT-E001); EBV-TCR-T (YT-E001) cells; YT-E001

Latest Information Update: 03 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator China Immunotech
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Nasopharyngeal cancer

Most Recent Events

  • 07 Nov 2019 Hebei Yanda Ludaopei Hospital plans a phase I trial for Epstein Barr virus infections after HSCT (Hematopoietic Stem Cell Transplantation) in China in December 2019 (NCT04156217)
  • 29 Aug 2018 Fujian Cancer Hospital and China Immunotech plans a pilot phase I/II trial for Nasopharyngeal cancer in China (IV) in October 2018 (NCT03648697)
  • 01 Mar 2018 Preclinical trials in Nasopharyngeal cancer in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top